The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing Tr1X’s pipeline of Type-1 regulatory T cells
In a clinical first, Tr1X Bio showed immune reconstitution and engraftment for allogeneic Tr1 cell therapy, establishing clinical safety and...
First clinical data from Phase 1 dose-escalation study in patients
In a clinical first, Tr1X Bio showed immune reconstitution and